A novel constitutional challenge to marijuana’s federal classification as a drug with a high probability of abuse and no medical use was shelved by the U.S. District Court for the Southern District of New York.
Under the law, the attorney general delegated reclassification decisions to the Drug Enforcement Agency, the opinion by Judge Alvin K. Hellerstein noted.
Because the plaintiffs, who use medical marijuana, didn’t exhaust their administrative remedies, their challenge must be dismissed, the court said Feb. 26.
Plaintiffs argued that leaving marijuana as a Schedule I drug violates due process because it lacks a rational basis. They also said it ran afoul of states’ rights.
The Justice Department argued that the plaintiffs first had to petition the DEA before suing the government.
Marijuana is used for medical treatment today and there is no rational basis for concluding otherwise, the court said. At bottom, however, the plaintiffs’ challenge is to the administrative decision not to reclassify the drug, it said.
The court emphasized that it wasn’t ruling on the merits of the claims and noted how marijuana has helped the plaintiffs’ treatment. Nevertheless, it tossed the case.
Plaintiffs represented by Hiller, PC vowed to appeal. The attorneys said in a statement to Bloomberg Law that the administrative process could take up to nine years, which could amount to a death sentence for some of the plaintiffs.
The Justice Department declined to comment.
With assistance from Melissa Heelan Stanzione
The case is Washington v. Sessions , 2018 BL 63683, S.D.N.Y., No 1:17-cv-05625, 2/26/18 .
To contact the reporter on this story: Bernie Pazanowski in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Jessie Kokrda Kamens at email@example.com
Copyright © 2018 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)